MGVS has developed a novel approach based on gene and cell therapy technology. The technology is being used by the company to provide a more effective solution for the narrowing of blood vessels in several vascular disorders. The company’s two major products provide an effective solution for the arrowing of blood vessels by: Accelerating the body’s natural process of creating new blood vessels (“natural bypasses”). Up-grading an existing artificial blood vessel (“graft”) which significantly improves the blood flow to both the heart and peripheral organs (legs and hands).
Investors 1
| Date | Name | Website |
| - | Aviv Ventu... | avivvc.com |